高尔基体蛋白73在原发性肝癌预后判断中的应用价值

目的 探讨血清高尔基体蛋白73（GP73）在原发性肝癌预后判断中的价值.方法 酶联免疫吸附试验定量检测血清GP73,分别测定63例原发性肝癌患者术前、术后（2周、4周）以及术后3～12个月复发的21例重新入院患者的GP73的浓度.结果 原发性肝癌患者术前GP73平均水平为（240.5±81.4） ng/ml,手术治疗后2周GP73平均浓度为（114.4±34.1）ng/ml,治疗后4周平均浓度为（57.6±23.3） ng/ml,治疗前浓度显著高于治疗后浓度（P＜0.05）.肝癌复发的患者重入院后GP73浓度（181.2±72.4） ng/ml]明显高于GP73术后的浓度（P＜0.05）.结论 GP73作为一个新型肝癌血清标记物在判断肝癌预后中具有较好的应用价值.

Clinical value of Golgi protein 73 in judging the prognosis of primary liver cancer

Objective To study postoperative monitoring value of serum Golgi protein 73 （GP73） in the primary hepatic carcinoma.Methods Serum GP73 was detected by using ELISA,in 63 patients with primary liver cancer,before surgery,2 and 4 weeks after operation and 21 recurrent cases who were readmitted 3-12 months later.Results In primary liver cancer patients before surgery average concentration of GP73 was （240.5 ± 81.4） ng/ml,while 2 weeks after surgical treatment the average concentration of GP73 was （114.4 ± 34.1） ng/ml,after 4 weeks was （57.6 ± 23.3） ng/ml,concentration of GP73 before treatment were significantly higher than the concentration after treatment （P 〈 0.05）.GP73 concentration （181.2 ±72.4） ng/ml] in patients with recurrence of hepatocellular carcinoma was significantly higher than the concentration after treatment （P 〈 0.05）.Conclusion GP73 is a new serum biomarker of hepatocellular carcinoma and had a good performance in monitoring prognosis of patients with hepatocellular carcinoma.